Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?

about

Treatment of extended-spectrum β-lactamase-producing (ESBLs) infections: what have we learned until now?

Item

http://www.wikidata.org/entity/Q58694612

description

scientific article published on 29 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Treatment of extended-spectrum ...... hat have we learned until now?

@en

Treatment of extended-spectrum β-lactamase-producing

@nl

type

Item

label

Treatment of extended-spectrum ...... hat have we learned until now?

@en

Treatment of extended-spectrum β-lactamase-producing

@nl

prefLabel

Treatment of extended-spectrum ...... hat have we learned until now?

@en

Treatment of extended-spectrum β-lactamase-producing

@nl

P1476

Treatment of extended-spectrum ...... hat have we learned until now?

@en

P2093

Zoi Dorothea Pana

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Carbapenems: past, present, and future

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamases: a systematic review and meta-analysis

Intravenous fosfomycin - Back to the future. Systematic review and meta-analysis of the clinical literature

Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies.

Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.

Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates.

Plazomicin: an investigational therapy for the treatment of urinary tract infections.

Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.

P304

1347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.12688/F1000RESEARCH.14822.1

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Zoi Dorothea Pana

P577

2018-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30228863

http://www.w3.org/2001/XMLSchema#string

P921

Añaki

mechanism of action

Anzim

P932

6117850

http://www.w3.org/2001/XMLSchema#string